Osmosis Investment Management UK Ltd acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,998 shares of the medical research company’s stock, valued at approximately $1,002,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Sanctuary Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $25,162,000. Solstein Capital LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $985,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Thermo Fisher Scientific in the second quarter worth $18,184,000. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $3,205,000. Finally, Forefront Analytics LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth about $336,000. 89.23% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Thermo Fisher Scientific
In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 73,493 shares of company stock valued at $43,950,381. Company insiders own 0.33% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock opened at $628.69 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The business’s 50 day simple moving average is $545.64 and its two-hundred day simple moving average is $509.60. The stock has a market capitalization of $232.46 billion, a P/E ratio of 33.82, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
